-
Mashup Score: 0Better Therapeutics wins FDA nod for diabetes digital therapeutic - 10 month(s) ago
Better Therapeutics (Nasdaq:BTTX) announced that the FDA authorized its AspyreRx prescription digital therapeutic for diabetes.
Source: Drug Delivery BusinessCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 2PharmaJet Tropis device exclusively delivers 2 COVID-19 vaccines - 10 month(s) ago
PharmaJet announced that its Tropis system is now the exclusive intradermal delivery system for two novel COVID-19 vaccines.
Source: Drug Delivery BusinessCategories: Infectious Disease, Latest HeadlinesTweet
-
Mashup Score: 0Embecta stock rises on Q2 results, raised full-year guidance - 12 month(s) ago
Embecta (Nasdaq:EMBC) shares ticked up today on second-quarter results that topped the consensus forecast, leading to a guidance increase.
Source: Drug Delivery BusinessCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 0Dexcom grows revenues 18% in Q1, raises guidance - 1 year(s) ago
Dexcom (Nasdaq:DXCM) today announced that it’s raising its 2023 financial guidance following strong first-quarter financial results.
Source: Drug Delivery BusinessCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 0
Insulet (Nasdaq:PODD) announced today that it received FDA clearance for its Omnipod GO long-acting insulin delivery device.
Source: Drug Delivery BusinessCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 0Senseonics announces first pediatric 365-day CGM insertion - 1 year(s) ago
Senseonics (NYSE:SENS) announced that the first pediatric study participant received an Eversense 365-day CGM insertion.
Source: Drug Delivery BusinessCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 1Dexcom, Abbott applaud Medicare expansion for CGMs - 1 year(s) ago
Dexcom and Abbott both commended a change to Medicare policies that benefits continuous glucose monitor (CGM) users.
Source: Drug Delivery BusinessCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 1FDA clears reader for next-gen Abbott FreeStyle Libre 3 - 1 year(s) ago
Abbott (NYSE:ABT) announced today that the FDA cleared a reader device for its FreeStyle Libre 3 continuous glucose monitoring (CGM) system.
Source: Drug Delivery BusinessCategories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 0Abbott warns on some FreeStyle Libre readers for battery issues - 1 year(s) ago
Abbott initiated a voluntary medical device correction to emphasize instructions for FreeStyle Libre continuous glucose monitor (CGM) readers.
Source: Drug Delivery BusinessCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 0Bigfoot Biomedical acquires insulin titration algorithm - 1 year(s) ago
Bigfoot Biomedical announced today that it acquired a reinforcement learning algorithm for insulin titration from McGill University.
Source: Drug Delivery BusinessCategories: Healthcare Professionals, Latest HeadlinesTweet
.@Better_Tx Therapeutics wins FDA nod for type 2 #diabetes #digitaltherapeutics | #DTx https://t.co/MK5y7tnVAS